The PET Radioligand [11C]MePPEP Binds Reversibly and with High Specific Signal to Cannabinoid CB1 Receptors in Nonhuman Primate Brain
暂无分享,去创建一个
Christer Halldin | Fumihiko Yasuno | Eyassu Chernet | Sami S Zoghbi | Christian C Felder | John M Schaus | Victor W Pike | Robert B Innis | Johannes Tauscher | F. Yasuno | C. Halldin | S. Zoghbi | R. Gladding | V. Pike | R. Innis | Jinsoo Hong | J. Krushinski | C. Felder | Amira K. Brown | J. Tauscher | L. Phebus | Jinsoo Hong | Robert L Gladding | Amira K Brown | Joseph H Krushinski | Lee A Phebus | Amy K Chesterfield | E. Chernet | J. Schaus | A. Chesterfield
[1] T. Vanderah,et al. The Cannabinoid Agonist WIN55,212-2 Suppresses Opioid-induced Emesis in Ferrets , 2001, Anesthesiology.
[2] R. Dannals,et al. Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. , 2000, Nuclear medicine and biology.
[3] M. Herkenham,et al. Cannabinoid receptor localization in brain. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[4] J. Herbert,et al. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. , 2002, Nuclear medicine and biology.
[5] Dean F. Wong,et al. 11 C-JHU 75528 : A Radiotracer for PET Imaging of CB 1 Cannabinoid Receptors , 2006 .
[6] M. Minchin,et al. Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.
[7] R. Faull,et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain , 1997, Neuroscience.
[8] M. Shen,et al. The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons , 1998, Brain Research.
[9] A. Wolf,et al. PET studies in the primate brain and biodistribution in mice using (−)-5′-18 F-Δ 8-THC , 1991, Pharmacology Biochemistry and Behavior.
[10] N. Volkow,et al. In vivo imaging of the brain cannabinoid receptor. , 2002, Chemistry and physics of lipids.
[11] N. Volkow,et al. Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281 , 2000, Synapse.
[12] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[13] Christopher P Cannon,et al. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors , 2006, Expert opinion on investigational drugs.
[14] M. Herkenham,et al. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.
[15] Makoto Inoue,et al. Template-Based Method for Multiple Volumes of Interest of Human Brain PET Images , 2002, NeuroImage.
[16] D. McClure,et al. Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. , 1999, The Journal of pharmacology and experimental therapeutics.
[17] Robert B. Innis,et al. SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: I. Kinetic Modeling of Single Bolus Experiments , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[18] M. Phelps,et al. Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PET , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] Arman Rahmim,et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] T. Reader,et al. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity. , 1989, The Journal of pharmacology and experimental therapeutics.
[21] A. Hoffman,et al. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. , 2003, Journal of medicinal chemistry.
[22] David G. Lambert,et al. Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist , 1996, Neuroscience Letters.
[23] D. Osei-Hyiaman,et al. Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.
[24] A. Hohmann,et al. The neurobiology of cannabinoid analgesia. , 1999, Life sciences.
[25] T. Kirkham,et al. Endocannabinoids in appetite control and the treatment of obesity. , 2006, CNS & neurological disorders drug targets.
[26] H. Akaike. A new look at the statistical model identification , 1974 .
[27] John H. Krystal,et al. Positron emission tomography and autoradiography: Principles and applications for the brain and heart , 1985 .
[28] D. Horrobin,et al. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.
[29] S. Zoghbi,et al. Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.
[30] John Cawley,et al. The determination of , 1993 .
[31] P. R. Bevington,et al. Data Reduction and Error Analysis for the Physical Sciences , 1969 .
[32] S. Goldberg,et al. Cannabinoid CB1 Receptor Antagonists as Promising New Medications for Drug Dependence , 2005, Journal of Pharmacology and Experimental Therapeutics.
[33] A. Wolf,et al. PET studies in the primate brain and biodistribution in mice using (-)-5'-18F-delta 8-THC. , 1991, Pharmacology, biochemistry, and behavior.
[34] Jeih-San Liow,et al. PET imaging of the dopamine transporter with 18F-FECNT: a polar radiometabolite confounds brain radioligand measurements. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] C. Halldin,et al. Saturation of striatal D(2) dopamine receptors by clozapine. , 2002, The international journal of neuropsychopharmacology.
[36] N. Volkow,et al. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. , 1996, European journal of pharmacology.
[37] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[38] C. Wandel,et al. Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.
[39] F. Yasuno,et al. Quantification of serotonin 5‐HT1A receptors in monkey brain with [11C](R)‐(−)‐RWAY , 2006, Synapse.